Ligand Buys Royalty Rights to Santen's Myopia Drug Ryjunea

Ligand Pharmaceuticals Inc. (LGND) said Tuesday it has acquired royalty and milestone payment rights tied to Santen Pharmaceutical Co. Ltd's Ryjunea, the first pharmacologic treatment approved in Europe and the UK to slow the progression of myopia in children.

Ligand Pharmaceuticals Inc. (LGND) said Tuesday that it has bought royalty and milestone payment rights attached to Ryjunea, Santen Pharmaceutical Co. Ltd's treatment for slowing the progression of myopia in children. Ryjunea is the first pharmacologic therapy approved for that use in Europe and the United Kingdom, which makes the asset an unusual one: a first-in-category product in a condition that has historically been managed with spectacles, contact lenses and behavioural advice rather than a prescribed drug.

Shares of Ligand were quoted at 292.81 in Tuesday trading, up 0.94% from the previous close of 290.07, with a session range of 289.00 to 292.85, as of 13:58 GMT. The move put the stock ahead of a flat broad market: the S&P 500 tracker (SPY) was at $774.10, up 0.08%, the Nasdaq 100 tracker (QQQ) at $744.91, up 0.46%, and the Dow tracker (DIA) at $519.45, down 0.06%.

What Ligand actually bought

Royalty acquisition is Ligand's business model rather than a one-off transaction. The company does not, in the main, run its own commercial sales force for these products. It provides capital to the parties who own economic interests in approved or near-approved medicines, and in exchange it takes a slice of future net sales plus, typically, payments triggered when defined commercial or regulatory milestones are hit. The result is a portfolio that behaves less like a single-product biotech and more like a diversified stream of contractual cash flows, each tied to someone else's execution.

In this case the counterparty product is Santen's Ryjunea, and the underlying performance risk sits with Santen's ability to launch and scale the drug across European and UK markets. Ligand's exposure is to the top line — the prescriptions written and reimbursed — rather than to Santen's manufacturing costs, sales overheads or pipeline decisions elsewhere. That is the attraction of the structure and also its limitation: royalty buyers capture the upside of a strong launch without controlling any of the levers that produce one.

The announcement, as Nasdaq Markets reported it, did not attach a headline dollar figure to the transaction. Without disclosed consideration, investors cannot yet judge the implied return, and the deal's contribution to Ligand's revenue and earnings guidance is not something that can be calculated from what has been made public.

Why a myopia drug is a different kind of royalty asset

Most royalty portfolios are weighted toward oncology, rare disease and specialty categories where patient numbers are small and per-patient prices are high. A paediatric myopia treatment inverts that arithmetic. Short-sightedness in children is common and rising in much of the world, and the clinical case for intervening early is that slowing progression during the growth years reduces the degree of myopia a patient carries into adulthood — and with it the long-term risk of the sight-threatening complications associated with high myopia.

That gives Ryjunea a potential patient base measured very differently from a typical specialty drug: broad, chronic, and identified through routine optometric and ophthalmic care rather than through specialist referral pathways. It also introduces a different set of commercial frictions. Reimbursement authorities across European health systems generally scrutinise treatments for conditions that are currently managed with devices and lifestyle measures, and a first-in-class approval does not automatically translate into national funding. Uptake will depend on country-by-country pricing decisions, prescriber adoption among eye-care professionals, and parental willingness to put a child on a long-run daily therapy.

For a royalty holder, those frictions matter in one direction only: they determine the shape and slope of the sales curve. Ligand has no say in how Santen negotiates in Germany or France, but it holds a claim on the outcome.

How the deal fits the portfolio logic

For a royalty holder, those frictions matter in one direction only: they determine the shape and slope of the sales curve.

The strategic point of adding an asset such as this is diversification of timing. Royalty streams tied to launched specialty products tend to ramp quickly and then face patent or competitive cliffs. A therapy entering a category that has no established pharmacologic competitor, in a condition that runs for years per patient, offers a longer and flatter profile — if it gains traction. Ligand is, in effect, trading near-term certainty for duration.

The milestone component is the other half of the structure. Milestone payments are lump sums triggered by defined events — commonly sales thresholds crossed, additional approvals secured, or new territories entered. They are binary in nature and hard to model, which is why royalty buyers usually treat them as optionality layered on top of the base royalty rather than as the core of the investment case.

It is worth noting what the market did not do on the news. A 0.94% gain, inside a session range of roughly three points, is a stock absorbing a portfolio addition rather than repricing on a transformational event. That is consistent with an undisclosed-terms deal in a business built on doing several such transactions a year.

What to watch from here

Three things will determine whether this purchase looks well-timed a year from now.

Disclosure of terms. If Ligand details the consideration and the royalty rate in a filing or on a results call, analysts will be able to back out the implied sales assumption and judge the price paid.
National reimbursement decisions. Ryjunea's European and UK approvals establish that the drug can be sold. Funding decisions in individual markets establish whether it will be. Each positive listing widens the addressable base that Ligand's royalty runs against.
Competitive entry. "First approved" is a description of today, not a moat. Other developers are working in paediatric myopia, and the arrival of a second pharmacologic option would change the pricing and share assumptions underpinning any royalty valuation.

For investors in Ligand specifically, the broader question is cumulative rather than deal-by-deal. A royalty aggregator is judged on the blended return across its book and on whether new additions extend the average life of that book faster than existing streams roll off. Ryjunea, as a first-in-category chronic paediatric therapy in two large regulated markets, is plausibly a duration-extending asset. Whether it is a value-accretive one depends on a number neither Ligand nor Santen has yet put on the table.

Key facts

Stock: LGND at 292.81, +0.94%, as of 22 Sep 2026 13:58 GMT
Transaction: Acquisition of royalty and milestone payment rights
Underlying asset: Santen Pharmaceutical's Ryjunea, for slowing myopia progression in children
Regulatory status: First approved pharmacologic myopia-progression treatment in Europe and the UK

Frequently asked questions

What did Ligand Pharmaceuticals announce?

Ligand Pharmaceuticals Inc. (LGND) said on Tuesday that it had acquired royalty and milestone payment rights tied to Ryjunea, a product of Santen Pharmaceutical Co. Ltd. Ryjunea is the first pharmacologic treatment approved in Europe and the United Kingdom to slow the progression of myopia in children. Financial terms were not detailed in the announcement.

What is Ryjunea used for?

Ryjunea is prescribed to slow the progression of myopia — short-sightedness — in children. It is the first medicine approved for that purpose in Europe and the UK, a condition that has traditionally been managed with corrective spectacles, contact lenses and behavioural measures rather than with a prescribed pharmacologic therapy.

How did Ligand's shares react?

Ligand traded at 292.81, up 0.94% from a previous close of 290.07, with a session range of 289.00 to 292.85 as of 13:58 GMT on 22 September 2026. That was a modest gain against a broadly flat market, with the S&P 500 tracker up 0.08% and the Nasdaq 100 tracker up 0.46% on the day.

How does a royalty acquisition work?

A royalty buyer pays capital upfront in exchange for a contractual share of a drug's future net sales, often alongside milestone payments triggered by defined events such as sales thresholds or additional approvals. The buyer gains exposure to the product's commercial performance without operating the sales, manufacturing or regulatory functions behind it.

What is the size of the Ligand-Santen deal?

The consideration was not disclosed in the announcement. Without a stated purchase price or royalty rate, the implied return and the contribution to Ligand's revenue and earnings cannot be calculated from public information. Any future disclosure in a filing or on a results call would allow analysts to model the economics.

What determines how much the royalty is worth?

Ultimately, Ryjunea's sales. Those depend on national reimbursement decisions across European health systems and the UK, adoption by eye-care prescribers, how long children remain on therapy, and whether competing pharmacologic myopia treatments reach the market and erode pricing or share. Ligand holds the economic claim but controls none of those variables.

Sources

Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug — Nasdaq Markets